A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine.

An important consideration in the development of subunit vaccines is the loss of activity caused by physical instability of the protein. Such instability often results from suboptimal solution conditions related to pH and temperature. Excipients can help to stabilize vaccines, but it is important to screen and identify excipients that adequately contribute to stabilization of a given formulation. CagL is a protein present in strains of Helicobacter pylori (H. pylori) that possess type IV secretion systems. It contributes to bacterial adherence via α5β1 integrin, thereby making it an attractive subunit vaccine candidate. We characterized the stability of CagL in different pH and temperature conditions using a variety of spectroscopic techniques. Stability was assessed in terms of transition temperature with the accumulated data, and then incorporated into an empirical phase diagram (EPD) that provided an overview of CagL physical stability. These analyses indicated maximum CagL stability at pH 4-6 up to 40°C in the absence of excipient. Using this EPD analysis, aggregation assays were developed to screen a panel of excipients with some found to inhibit CagL aggregation. Candidate stabilizers were selected to confirm their enhanced stabilizing effect. These analyses will help in the formulation of a stable vaccine against H. pylori.

[1]  L. Peek,et al.  Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. , 2007, Journal of pharmaceutical sciences.

[2]  S. Czinn,et al.  Vaccinating against Helicobacter pylori infection , 2011, Nature Reviews Gastroenterology &Hepatology.

[3]  R. Rappuoli,et al.  Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Haas,et al.  Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin‐8 , 2001 .

[5]  Fred E. Silverstein,et al.  Helicobacter pylori in peptic ulcer disease. , 1994, NIH consensus statement.

[6]  Tim J Kamerzell,et al.  Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. , 2011, Advanced drug delivery reviews.

[7]  R. K. Evans,et al.  Development of stable liquid formulations for adenovirus-based vaccines. , 2004, Journal of pharmaceutical sciences.

[8]  M. Naumann,et al.  Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus , 2000, Cellular microbiology.

[9]  K. Jung,et al.  Helicobacter pylori Type IV Secretion Apparatus Exploits β1 Integrin in a Novel RGD-Independent Manner , 2009, PLoS pathogens.

[10]  L. Peek,et al.  A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. , 2006, Vaccine.

[11]  W William Wilson,et al.  Light scattering as a diagnostic for protein crystal growth--a practical approach. , 2003, Journal of structural biology.

[12]  S. Falkow,et al.  Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Guy,et al.  Systemic immunization with urease protects mice against Helicobacter pylori infection. , 1998, Vaccine.

[14]  R. Haas,et al.  Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. , 2000, Science.

[15]  L. Peek,et al.  Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens* , 2005, Journal of Biological Chemistry.

[16]  N. A. Rodionova,et al.  Study of the “molten globule” intermediate state in protein folding by a hydrophobic fluorescent probe , 1991, Biopolymers.

[17]  Carl-Fredrik Flach,et al.  A Double Mutant Heat-Labile Toxin from Escherichia coli, LT(R192G/L211A), Is an Effective Mucosal Adjuvant for Vaccination against Helicobacter pylori Infection , 2013, Infection and Immunity.

[18]  J. Lee,et al.  The stabilization of proteins by sucrose. , 1981, The Journal of biological chemistry.

[19]  Maya S. Salnikova,et al.  Preformulation studies of Clostridium difficile toxoids A and B. , 2008, Journal of pharmaceutical sciences.

[20]  Wim Jiskoot,et al.  Extrinsic Fluorescent Dyes as Tools for Protein Characterization , 2008, Pharmaceutical Research.

[21]  E. H. Strickland,et al.  Aromatic contributions to circular dichroism spectra of proteins. , 1974, CRC critical reviews in biochemistry.

[22]  S. Czinn,et al.  Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. , 1999, Cellular immunology.

[23]  N. C. Price,et al.  The use of circular dichroism in the investigation of protein structure and function. , 2000, Current protein & peptide science.

[24]  P. Sutton,et al.  Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies , 2000, Immunology and cell biology.

[25]  C. Wiethoff,et al.  Thermal stability of vaccines. , 2003, Journal of pharmaceutical sciences.

[26]  Helicobacter pylori Caga Protein Can Be Tyrosine Phosphorylated in Gastric Epithelial Cells , 2000 .

[27]  Ross D. Shachter,et al.  Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. , 2001, Vaccine.

[28]  D. A. Dougherty,et al.  Cation-π Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, and Trp , 1996, Science.

[29]  P. Sutton,et al.  Helicobacter pylori vaccines , 2010 .

[30]  J. Baldridge,et al.  Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. , 1999, Methods.

[31]  B. Marshall,et al.  UNIDENTIFIED CURVED BACILLI ON GASTRIC EPITHELIUM IN ACTIVE CHRONIC GASTRITIS , 1983, The Lancet.

[32]  Satoshi Ohtake,et al.  Interactions of formulation excipients with proteins in solution and in the dried state. , 2011, Advanced drug delivery reviews.

[33]  A. Labigne,et al.  The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Adel Golovin,et al.  Cation–π interactions in protein–protein interfaces , 2005 .

[35]  W. C. Johnson,et al.  Secondary structure of proteins through circular dichroism spectroscopy. , 1988, Annual review of biophysics and biophysical chemistry.

[36]  V. N. Kazakov,et al.  Dynamics of protein and mixed protein/surfactant adsorption layers at the water/fluid interface. , 2000, Advances in colloid and interface science.

[37]  B. Guy,et al.  Mucosal, systemic, or combined therapeutic immunizations in cynomolgus monkeys naturally infected with Gastrospirillum hominis-like organisms , 1997 .

[38]  H. Ehrlich,et al.  History of TBE vaccines. , 2003, Vaccine.

[39]  Roland Hartig,et al.  Helicobacter exploits integrin for type IV secretion and kinase activation , 2007, Nature.

[40]  T. Monath,et al.  Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. , 1999, Vaccine.

[41]  W C Johnson,et al.  Protein secondary structure and circular dichroism: A practical guide , 1990, Proteins.

[42]  B. Marshall,et al.  UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATION , 1984, The Lancet.

[43]  J Robinwarren,et al.  UNIDENTIFIED CURVED BACILLI ON GASTRIC EPITHELIUM IN ACTIVE CHRONIC GASTRITIS , 1983 .

[44]  S. Joshi,et al.  Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. , 2013, Journal of pharmaceutical sciences.

[45]  T. Monath,et al.  Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses , 1998, The Journal of experimental medicine.

[46]  J. Clements,et al.  Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant , 2011, Clinical and Vaccine Immunology.

[47]  S. Czinn,et al.  Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. , 2001, The Journal of infectious diseases.

[48]  S. Joshi,et al.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.

[49]  N. C. Price,et al.  How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.

[50]  T. Monath,et al.  Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. , 1996, Gastroenterology.